Following a thorough safety review, including two meetings of the CDC\u2019s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.<\/p>\n\n\n\n
The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen COVID-19 Vaccine. During the pause, medical and scientific teams at the FDA and CDC examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body (including but not limited to the large blood vessels of the abdomen and the veins of the legs) along with thrombocytopenia, or low blood platelet counts.<\/p>\n\n\n\n
Teams at the FDA and CDC also conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognize these events due to the unique treatment required for these blood clots and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS).<\/p>\n\n\n\n
The two agencies have determined the following:<\/p>\n\n\n\n
\u00b7 Use of the Janssen COVID-19 Vaccine should be resumed in the United States.<\/p>\n\n\n\n
\u00b7 The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19.<\/p>\n\n\n\n
\u00b7 The FDA has determined that the available data show that the vaccine\u2019s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.<\/p>\n\n\n\n
\u00b7 At this time, the available data suggest that the chance of TTS occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.<\/p>\n\n\n\n
\u00b7 Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.<\/p>\n\n\n\n
CDC\u2019s independent Advisory Committee on Immunization Practices met to discuss the latest data on TTS, hearing from the vaccine manufacturer Janssen and the COVID-19 Vaccine Safety Technical (VaST) Subgroup, as well as a risk benefit analysis. ACIP is committed to be vigilant and responsive to additional information that could impact the risk benefit analysis of any of these vaccines. Vaccine safety monitoring will continue and any new information about TTS will be brought to ACIP as needed.<\/p>\n\n\n\n
\u201cSafety is our top priority. This pause was an example of our extensive safety monitoring working as they were designed to work – identifying even these small number of cases. We\u2019ve lifted the pause based on the FDA and CDC\u2019s review of all available data and in consultation with medical experts and based on recommendations from the CDC\u2019s Advisory Committee on Immunization Practices. We have concluded that the known and potential benefits of the Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older. We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality. We recommend people with questions about which vaccine is right for them have those discussions with their health care provider,\u201d said Janet Woodcock, M.D., Acting FDA Commissioner.<\/p>\n\n\n\n
\u201cAbove all else, health and safety are at the forefront of our decisions,\u201d said CDC Director Dr. Rochelle P. Walensky. \u201cOur vaccine safety systems are working. We identified exceptionally rare events – out of millions of doses of the Janssen COVID-19 administered – and we paused to examine them more carefully. As we always do, we will continue to watch all signals closely as more Americans are vaccinated. I continue to be encouraged by the growing body of real-world evidence that the authorized COVID-19 vaccines are safe and effective, and they protect people from disease, hospitalization, and death. I urge anyone with questions about the COVID-19 vaccines to speak with their healthcare provider or local public health department.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Following a thorough safety review, including two meetings of the CDC\u2019s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the U.S. should be lifted and […]<\/p>\n","protected":false},"author":2,"featured_media":2299,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[47],"tags":[],"class_list":["post-2616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"yoast_head":"\n